A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes
Background. Sodium glucose cotransport (SGLT)-2 inhibitors are the newest class of antihyperglycemic agents used as second- or third-line treatment in the management of type 2 diabetes. Although the use of SGLT-2 inhibitors has not been shown to cause nephrotoxicity, there have been case reports of...
Saved in:
| Main Authors: | Kimya Hassani-Ardakania, Mark L. Lipman, Denny Laporta, Oriana Hoi Yun Yu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2019/8639629 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Canagliflozin‐induced renal glutathione distribution mapping in non‐diabetic male rat kidneys
by: Guy Watanabe, et al.
Published: (2025-04-01) -
Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern
by: Alehegn Gelaye, et al.
Published: (2016-01-01) -
The role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolution
by: M. V. Shestakova, et al.
Published: (2023-11-01) -
Release of HMGB1 in Podocytes Exacerbates Lipopolysaccharide-Induced Acute Kidney Injury
by: Zhao Gao, et al.
Published: (2021-01-01) -
Effect of canagliflozin combined with alfacalcidol in the treatment of elderly type 2 diabetes mellitus with osteoporosis
by: HUANG Yi*,JIANGXiong,PENG Jun,GUI Xiao,LIU Shuang,LI Peng,LI Yanling,JIANG Meiling
Published: (2025-07-01)